Warning: Parameter 2 to flowplayer3_swftools_flashvars() expected to be a reference, value given in module_invoke() (line 476 of /var/www/pressflow/includes/module.inc).
In an almost unprecedented joint announcement, the FDA and European regulators announced that access to Avandia, a medication to treat diabetes marketed by GlaxoSmithKline, will be severely restricted. Read more »
Today it was reported that GSK has settled more than 700 Avandia cases for a sum reported to be approximately 60 million dollars. These are the first reported settlements involving the drug and represent a small fraction of the total claims believed to be pending. The average settlement would appear to be around 90-95 thousand dollars per case. Read more »
Diabetics from 18 states who suffered heart attacks or other cardiovascular injuries while taking Avandia only have a short time left to file a claim for compensation. The right to file a claim for compensation is subject to a statute of limitations. Read more »
According to a Dow Jones report, Saudi Arabia has suspended GlaxoSmithKline PLC's (GSK) diabetes drug Avandia from the market for six months. The Saudi authorities found that Avandia's heart risks did not outweigh its benefits. Read more »
In a study published in the British Medical Journal, researchers from the Mayo Clinic after examining more than 200 articles addressing the safety and efficacy of Avandia concluded that, "[a]uthors who had favourable views on the safety of rosiglitazone were more likely to have a financial conflict of intere Read more »
A GlaxoSmithKline funded study called RECORD, which allegedly exculpated the pill from increasing the risk of cardiovascular disease, was labeled by some physicians as “flawed” and the study cannot l Continue reading ⇒
Drug side effects many times cannot be determined when the drug is approved. They can only be found after millions of people use the drugs and report the results. Continue reading ⇒
Avandia (generically known as rosiglitazone) is a form of thiazolidinedione drug commonly used to lower blood glucose levels in patients with type 2 diabetes. Thiazolideinesdiones, prescribed in normal doses, decrease glycated hemoglobin levels by an average of about 1 one percentage point or less. Continue reading ⇒
The Cleveland Clinic has found that while Avandia increases tthe risks of heart attack, stroke and death, its chief competitior Actos, lowers the risk of heart attack, stroke and death in patients who use Actos to manage diabetes. Continue reading ⇒
